Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Burzynski Research InstituteBZYR Equity-to-Asset is -33.50 as of Nov. 2025. Among 1,415 Biotechnology companies, Burzynski Research Institute ranks worse than 99.43% on this metric.
The historical rank and industry rank for Burzynski Research Institute's Equity-to-Asset or its related term are showing as below:
BZYR'
s Equity-to-Asset Range Over the Past 10 Years
Min: -128 Med: -15.39 Max: 0.71
Current: -33.5
During the past 13 years, the highest Equity to Asset Ratio of Burzynski Research Institute was 0.71. The lowest was -128.00. And the median was -15.39.
BZYR's Equity-to-Asset is ranked worse than 99.43% of 1415
companies
in the Biotechnology industry
Industry Median: 0.68
vs BZYR: -33.50
Burzynski Research Institute (OTCPK:BZYR) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Burzynski Research Institute Equity-to-Asset Related Terms
Burzynski Research Institute Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Burzynski Research Institute Equity-to-Asset Chart
BZYR vs RMTG, EVFM, CLSDQ: Equity-to-Asset Comparison
For the Biotechnology subindustry, Burzynski Research Institute's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Burzynski Research Institute Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Burzynski Research Institute's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Burzynski Research Institute's Equity-to-Asset falls into.
Burzynski Research Institute Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Burzynski Research Institute's Equity to Asset Ratio for the fiscal year that ended in Feb. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Burzynski Research Institute (BZYR) has a Equity-to-Asset of -33.50 as of Nov. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Burzynski Research Institute and its competitors. According to the industry distribution chart, Burzynski Research Institute ranks #1407 out of 1415 companies in the Biotechnology industry, placing it in the top 99.4%.
Is Burzynski Research Institute's Equity-to-Asset too high?
Burzynski Research Institute's current Equity-to-Asset is -33.50. Based on the distribution chart, Burzynski Research Institute ranks #1407 out of 1415 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Burzynski Research Institute's Equity-to-Asset compare to RMTG and EVFM?
According to the Biotechnology industry distribution chart, Burzynski Research Institute ranks #1407 out of 1415 companies for Equity-to-Asset. This places Burzynski Research Institute in the lower half of its industry. The industry median Equity-to-Asset is 0.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Burzynski Research Institute and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Burzynski Research Institute's current Equity-to-Asset is -33.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Burzynski Research Institute stock overvalued right now?
Burzynski Research Institute (BZYR) has a current Equity-to-Asset of -33.50. The current Equity-to-Asset is -33.50. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Burzynski Research Institute (BZYR), the current Equity-to-Asset is -33.50 as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Burzynski Research Institute Inc operates as a research and development facility of Antineoplaston drugs currently being tested for the use in the treatment of cancer, and provides consulting services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BZYR has been successfully added to your 
